Tariq I. Mughal – författare

Our understanding of myeloproliferative neoplasms (MPN) disorders, a group of clonal haematological malignancies characterized by excessive accumulation of one or more myeloid cell lineages, has grown considerably over the past four decades.Myeloproliferative Neoplasms offers a detailed evidence-based guide to MPNs in an easily accessible format, structured to facilitate learning specialist information by presenting core information in ''bite size'' chunks. Each chapter summarises the state-of-the art preclinical and clinical knowledge, and its impact on the clinical management of patients with MPNs. This practical guide, written by experts in the field, is essential reading for oncologists, haematologists, and other health care professionals interested in the field of MPNs.

Our understanding of myeloproliferative neoplasms (MPN) disorders, a group of clonal haematological malignancies characterized by excessive accumulation of one or more myeloid cell lineages, has grown considerably over the past four decades.Myeloproliferative Neoplasms offers a detailed evidence-based guide to MPNs in an easily accessible format, structured to facilitate learning specialist information by presenting core information in ''bite size'' chunks. Each chapter summarises the state-of-the art preclinical and clinical knowledge, and its impact on the clinical management of patients with MPNs. This practical guide, written by experts in the field, is essential reading for oncologists, haematologists, and other health care professionals interested in the field of MPNs.

Our understanding of myeloproliferative neoplasms (MPN) disorders, a group of clonal haematological malignancies characterized by excessive accumulation of one or more myeloid cell lineages, has grown considerably over the past four decades.Myeloproliferative Neoplasms offers a detailed evidence-based guide to MPNs in an easily accessible format, structured to facilitate learning specialist information by presenting core information in 'bite size' chunks. Each chapter summarises the state-of-the art preclinical and clinical knowledge, and its impact on the clinical management of patients with MPNs. This practical guide, written by experts in the field, is essential reading for oncologists, haematologists, and other health care professionals interested in the field of MPNs.

A brand-new edition of the bestselling guide to hematologic malignancies.

An international team of contributors come together to present all clinically relevant aspects of leukemias, lymphomas, and myelomas. Using clear terminology, the book discusses salient features, diagnostic procedures, prognosis, and treatments for these cancers.

Following on the successful steps of the first edition, this Second Edition covers:

various types of leukemias, lymphomas, and myelomas utilizing stem cell transplantation side-effects of various treatments future prospects for leukemia, lymphoma, and myeloma targeted therapies and history of the cancers information and support sources for patients.

A brand-new edition of the bestselling guide to hematologic malignancies.An international team of contributors come together to present all clinically relevant aspects of leukemias, lymphomas, and myelomas. Using clear terminology, the book discusses salient features, diagnostic procedures, prognosis, and treatments for these cancers.Following on the successful steps of the first edition, this Second Edition covers: various types of leukemias, lymphomas, and myelomas utilizing stem cell transplantationside-effects of various treatmentsfuture prospects for leukemia, lymphoma, and myelomatargeted therapies and history of the cancersinformation and support sources for patients

A brand-new edition of the bestselling guide to hematologic malignancies.An international team of contributors come together to present all clinically relevant aspects of leukemias, lymphomas, and myelomas. Using clear terminology, the book discusses salient features, diagnostic procedures, prognosis, and treatments for these cancers.Following on the successful steps of the first edition, this Second Edition covers: various types of leukemias, lymphomas, and myelomas utilizing stem cell transplantation side-effects of various treatments future prospects for leukemia, lymphoma, and myeloma targeted therapies and history of the cancers information and support sources for patients.

Highly Commended, BMA Medical Book Awards 2014Chronic myeloid leukemia is a clonal disease that results from an acquired genetic change in a single pluripotential hemopoietic stem cell. Efforts to confront this disease have been assisted by advances in cellular and molecular biology and the speed at which these findings have transformed the therapeutic algorithm. Nevertheless, there is some uncertainty with regards to how best to assess efficacy of treatment, especially with regards to the most appropriate surrogate markers for overall survival. From the standpoint of biology and clinical management, this handbook provides an authoritative state-of-the-art review of current and developing progress.

A brand-new edition of the bestselling guide to hematologic malignancies.An international team of contributors come together to present all clinically relevant aspects of leukemias, lymphomas, and myelomas. Using clear terminology, the book discusses salient features, diagnostic procedures, prognosis, and treatments for these cancers.Following on the successful steps of the first edition, this Second Edition covers: various types of leukemias, lymphomas, and myelomas utilizing stem cell transplantationside-effects of various treatmentsfuture prospects for leukemia, lymphoma, and myelomatargeted therapies and history of the cancersinformation and support sources for patients

Highly Commended, BMA Medical Book Awards 2014Chronic myeloid leukemia is a clonal disease that results from an acquired genetic change in a single pluripotential hemopoietic stem cell. Efforts to confront this disease have been assisted by advances in cellular and molecular biology and the speed at which these findings have transformed the therapeutic algorithm. Nevertheless, there is some uncertainty with regards to how best to assess efficacy of treatment, especially with regards to the most appropriate surrogate markers for overall survival. From the standpoint of biology and clinical management, this handbook provides an authoritative state-of-the-art review of current and developing progress.